Filing Flows › Gossamer Bio (GOSS) › Recalls, complaints & regulation
Gossamer Bio (GOSS): clinical trials
Gossamer Bio (GOSS) beyond its filings: 1 active clinical trial.
Gossamer Bio's latest quarter
Gossamer Bio, Q2 2026: revenue $9.2M (-20% year over year), operating margin -282.2%, net earnings $16.9M, operating cash flow −$39.4M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Gossamer Bio have?
1 active study on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.